Table 1.
Demographic
| N | % | |
|---|---|---|
| PATIENTS | 18 | |
| GENDER | ||
| M | 8 | 44.4% |
| F | 10 | 55.6% |
| DIAGNOSIS | ||
| Colorectal cancer | 38.9% | |
| Breast cancer | 22.2% | |
| Hepatocellular cancer | 11.1% | |
| Ovarian cancer | 11.1% | |
| Anal cancer | 5.6% | |
| Cancer of unknown primary origin (CUP) | 5.6% | |
| Non-small cell lung cancer (NSCLC) | 5.6% | |
| TUMOURS TREATED | 21 | |
| LIVER METASTASES | ||
| Synchronous | 44.4% | |
| Metachronous | 44.4% | |
| No | 2 | 11.2% |
| METASTASES LOCATION | ||
| Liver only | 7 | 43.7% |
| Liver + lung | 21.5% | |
| Liver + bone | 6.2% | |
| Liver + kidney | 6.2% | |
| Liver + lung + bone + brain | 6.2% | |
| Liver + bone + peritoneum | 6.2% | |
| Liver + pleural + bone | 6.2% | |
| Liver + retroperitoneal | 6.2% | |
| PREVIOUS TREATMENTS | ||
| Systemic therapy | 16 | 88.8% |
| Liver surgery | 4 | 22.2% |
| TACE | 44.4% | |
| TACE + RFA | 5.6% | |
| TACE + CP | 5.6% | |
| CRYOTH | 5.6% | |
| NO | 38.9% | |
| COMORBIDITIES* | ||
| Cardiac diseases | 33.3% | |
| Pulmonary diseases | 16.7% | |
| Liver diseases | 50.0% |
* Cardiac diseases were cardiomyopathies, status post coronary bypass, status post aortocoronary venous bypass operation, valvular disease, pericardial effusion; pulmonary diseases were chronic obstructive pulmonary diseases; liver diseases were hematomas, ascites, cholestasis, hemochromatosis
CP = chemoperfusion; CRYOTH = cryotherapy; F = female; M = male; N = number; RFA = radiofrequency ablation; TACE = hepatic artery chemoembolization